Kalaris Therapeutics Raises $50M as Early Trial Risks Raise Questions
Kalaris Therapeutics (KLRS) secured $50 million in oversubscribed funding at a premium to support its eye drug, TH103. However, small trials, safety concerns, and lengthy timelines create uncertainty.